| Teva Pharm宣布，医药与医疗产品监管机构Agencyhas批准扩大Copaxone (glatiramer acetate injection)标签范围，包括治疗多发性硬化症(MS)病患，这份许可证适用於24个欧盟会员国。
干扰素无效的MS病人换用Copaxone后减少复发 复发缓解型多发性硬化症（MS）对Avonex（β-1a干扰素）没有反应的，换用非干扰素药Copaxone后复发明显减少。 这个前瞻性研究共纳入85名服用Avonex18-24个月的病人，均对Avonex无反应或有不可忍受的副作用，换用Copaxone并随访36-42个月，得到其中79人的随访资料。该研究评估了年平均复发数和无劳动能力拓宽量表(EDSS)上的内容，其结论表明病人换药后复发减少58%，从年平均1.13次复发减少到0.47次（p=0.0001），且按EDSS记录的神经性失能状态没有恶化。 “我们看见Avonex无效的病人换用Copaxone后出现最大改善”，美国韦恩州立大学多发性硬化症中心的神经学副教授汉恩（Omar Khan）说，“对病人三年多的随访表明复发率持续减少而神经性失能没有增加――即使这是个三年多的前瞻性开放研究，我们应慎重得出结论。总之，这个研究确实提供了有意义的信息，神经科医生应考虑给其它药物失败的MS病人换药，Copaxone是复发缓解型MS有效的一线药物，适于替代每周小剂量肌内注射的β-1a干扰素”。 在因缺乏有效性而换药的亚组，Avonex和Copaxone在减少复发率上的差异最为明显（分别是1.29和0.48）(p=0.0001)，“复发缓解型MS病人正在用免疫调节药和疾病在活性期的，可能因换药受益”。论文提交者、MS中心的考恩（Christina Caon）说，“我们的这个观察性研究可以帮助临床医生，向他们建议换药选择，但是，还需要制定何时换药的指针或标准”。 Copaxone适用于减少复发缓解型MS复发的频率，最常见的副作用是注射局部的红、肿、痒或包块、无力、感染、疼痛、恶心、关节痛和肌肉僵硬。全世界已有42个国家批准，包括美国、加拿大、澳大利亚、以色列和所有欧洲国家。在欧洲由Teva制药公司和Aventis公司上市，在北美由Teva神经科学公司上市。 Glatiramer (Copaxone) 可舒松注射剂
Copaxone( 20 mg for Solution for Injection 复发型多发性硬化症,Copaxone用於减少复发型多发性硬化症病人的复发频率.
关于克帕松(Copaxone)减少大脑内的“黑洞”的问题 关于克帕松(Copaxone)减少大脑内的“黑洞”的原因,关于克帕松(Copaxone)减少大脑内的“黑洞”的相关知识。 发表于8期《神经病学》上的一项研究显示，克帕松(注射用glatiramer acetate)可使复发-缓解多发性硬化患者中产生的持久性“黑洞”减少50%。黑洞是多发性硬化在大脑中可以引起的损害，这种损害，如果是持久性的，代表已经发生了最严重和不可逆的大脑组织损害区域。得克萨斯州健康科学中心大学多发性硬化研究组的研究人员称，该研究是设计来确定克帕松能否改变多发性硬化患者损害中的组织破坏。他们知道，持久性黑洞代表大脑损害最严重的区域。该研究证实，该研究似乎能够预防最新增强损害后某些迟发性组织破坏。该研究评价了239例(119例克帕松，120例安慰剂)多发性硬化患者的1722处新损害，这些患者登记加入了安慰剂对照克帕松MRI试验。研究人员通过每月一次大脑MRI扫描监测这些患者。这些扫描测定了大脑中几种类型损害的数目和大小。在随后每月一次的扫描中，研究人员评价了新增强损害形成后组织中的系列变化。随访几个月后，克帕松治疗患者随访扫描黑洞的百分率低于安慰剂治疗患者。7个月时，损害的损害仍为黑洞的百分率克帕松治疗患者为18.9%安慰剂为26.3%，P值为0.04。8个月时，克帕松治疗组为15.6%，对照为31.%，P值为0.002。克帕松适用于复发-缓解性多发性硬化的复发的减少。克帕松最常见的负作用为注射部位发红、疼痛、肿胀或肿块，脸红、胸痛、无力、感染、疼痛、恶心、关节疼痛、焦虑和肌肉僵硬等。这些反应通常都很轻微，很少需要专业的处理。患者应把负作用告诉他们的医生。某些患者诉注射克帕松后即刻出现短期反应，这种反应包括脸红(热和/或红的感觉)，胸部紧迫感伴有心悸的疼痛，焦虑和呼吸困难。这些症状通常在注射后数分钟内出现，持续大约15分钟，并且自行消失，没有任何进一步的问题。
COPAXONE (glatiramer acetate) injection, solution HIGHLIGHTS OF PRESCRIBING INFORMATION COPAXONE (glatiramer acetate) injection, solution for subcutaneous use RECENT MAJOR CHANGES DOSAGE AND ADMINISTRATION DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact TEVA at 1-800-221-4026 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 06/2009 1 INDICATIONS AND USAGE COPAXONE is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dose COPAXONE is for subcutaneous use only. Do not administer intravenously. The recommended dose of COPAXONE is 20 mg/day. 2.2 Instructions for Use Remove one blister that contains the syringe from the COPAXONE prefilled syringes package. Since this product should be refrigerated, let the prefilled syringe stand at room temperature for 20 minutes to allow the solution to warm to room temperature. Inspect the COPAXONE syringe visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution in the syringe should appear clear, colorless to slightly yellow. If particulate matter or discoloration is observed, discard the COPAXONE syringe. Areas for self-injection include arms, abdomen, hips, and thighs. The prefilled syringe is for single use only. Discard unused portions. 3 DOSAGE FORMS AND STRENGTHS Single-use prefilled syringe containing 1 mL solution with 20 mg of glatiramer acetate and 40 mg of mannitol. 4 CONTRAINDICATIONS COPAXONE is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. 5 WARNINGS AND PRECAUTIONS 5.1 Immediate Post-Injection Reaction Approximately 16% of patients exposed to COPAXONE in the 5 placebo-controlled trials compared to 4% of those on placebo experienced a constellation of symptoms immediately after injection that included at least two of the following: flushing, chest pain, palpitations, anxiety, dyspnea, constriction of the throat, and urticaria. The symptoms were generally transient and self-limited and did not require treatment. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience one or several episodes of these symptoms. Whether or not any of these symptoms actually represent a specific syndrome is uncertain. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. Whether an immunologic or nonimmunologic mechanism mediates these episodes, or whether several similar episodes seen in a given patient have identical mechanisms, is unknown. 5.2 Chest Pain Approximately 13% of COPAXONE patients in the 5 placebo-controlled studies compared to 6% of placebo patients experienced at least one episode of what was described as transient chest pain. While some of these episodes occurred in the context of the Immediate Post-Injection Reaction described above, many did not. The temporal relationship of this chest pain to an injection of COPAXONE was not always known. The pain was transient (usually lasting only a few minutes), often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than one such episode, and episodes usually began at least 1 month after the initiation of treatment. The pathogenesis of this symptom is unknown. 5.3 Lipoatrophy and Skin Necrosis At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis have been reported during the postmarketing experience. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy. To assist in possibly minimizing these events, the patient should be advised to follow proper injection technique and to rotate injection sites daily. 5.4 Potential Effects on Immune Response Because COPAXONE can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE may interfere with the recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that COPAXONE does this, but there has not been a systematic evaluation of this risk. Because COPAXONE is an antigenic material, it is possible that its use may lead to the induction of host responses that are untoward, but systematic surveillance for these effects has not been undertaken. Although COPAXONE is intended to minimize the autoimmune response to myelin, there is the possibility that continued alteration of cellular immunity due to chronic treatment with COPAXONE may result in untoward effects. Glatiramer acetate-reactive antibodies are formed in most patients exposed to daily treatment with the recommended dose. Studies in both the rat and monkey have suggested that immune complexes are deposited in the renal glomeruli. Furthermore, in a controlled trial of 125 RRMS patients given COPAXONE, 20 mg, subcutaneously every day for 2 years, serum IgG levels reached at least 3 times baseline values in 80% of patients by 3 months of initiation of treatment. By 12 months of treatment, however, 30% of patients still had IgG levels at least 3 times baseline values, and 90% had levels above baseline by 12 months. The antibodies are exclusively of the lgG subtype and predominantly of the lgG-1 subtype. No lgE type antibodies could be detected in any of the 94 sera tested; nevertheless, anaphylaxis can be associated with the administration of most any foreign substance, and therefore, this risk cannot be excluded. 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Incidence in Controlled Clinical Trials Among 563 patients treated with COPAXONE in blinded placebo controlled trials, approximately 5% of the subjects discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were: injection site reactions, dyspnea, urticaria, vasodilatation, and hypersensitivity. The most common adverse reactions were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain. Table 1 lists treatment-emergent signs and symptoms that occurred in at least 2% of patients treated with COPAXONE in the placebo-controlled trials. These signs and symptoms were numerically more common in patients treated with COPAXONE than in patients treated with placebo. Adverse reactions were usually mild in intensity.
Adverse reactions which occurred only in 4-5 more subjects in the COPAXONE group than in the placebo group (less than 1% difference), but for which a relationship to COPAXONE could not be excluded, were arthralgia and herpes simplex. Laboratory analyses were performed on all patients participating in the clinical program for COPAXONE. Clinically significant laboratory values for hematology, chemistry, and urinalysis were similar for both COPAXONE and placebo groups in blinded clinical trials. In controlled trials one patient discontinued treatment due to thrombocytopenia (16 x109/L), which resolved after discontinuation of treatment. Data on adverse reactions occurring in the controlled clinical trials were analyzed to evaluate differences based on sex. No clinically significant differences were identified. Ninety-six percent of patients in these clinical trials were Caucasian. The majority of patients treated with COPAXONE were between the ages of 18 and 45. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically relevant age subgroups. Other Adverse Reactions In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled premarketing studies (n= 979), the role of COPAXONE in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used COPAXONE and reported a reaction divided by the total number of patients exposed to COPAXONE. All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent adverse reactions are defined as those occurring in at least 1/100 patients and infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients. Body as a Whole:
Cardiovascular:
Digestive:
Endocrine:
Gastrointestinal:
Hemic and Lymphatic:
Metabolic and Nutritional:
Musculoskeletal:
Nervous:
Respiratory:
Skin and Appendages:
Special Senses:
Urogenital:
6.2 Postmarketing Experience Reports of adverse events occurring under treatment with COPAXONE not mentioned above that have been received since market introduction and may or may not have causal relationship to COPAXONE are listed below. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole: sepsis; SLE syndrome; hydrocephalus; enlarged abdomen; injection site hypersensitivity; allergic reaction; anaphylactoid reaction Cardiovascular System: thrombosis; peripheral vascular disease; pericardial effusion; myocardial infarct; deep thrombophlebitis; coronary occlusion; congestive heart failure; cardiomyopathy; cardiomegaly; arrhythmia; angina pectoris Digestive System: tongue edema; stomach ulcer; hemorrhage; liver function abnormality; liver damage; hepatitis; eructation; cirrhosis of the liver; cholelithiasis Hemic and Lymphatic System: thrombocytopenia; lymphoma-like reaction; acute leukemia Metabolic and Nutritional Disorders: hypercholesterolemia Musculoskeletal System: rheumatoid arthritis; generalized spasm Nervous System: myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain edema; abnormal dreams; aphasia; convulsion; neuralgia Respiratory System: pulmonary embolus; pleural effusion; carcinoma of lung; hay fever Special Senses: glaucoma; blindness; visual field defect Urogenital System: urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; bladder carcinoma; urinary frequency 7 DRUG INTERACTIONS Interactions between COPAXONE and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of COPAXONE with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. COPAXONE has not been formally evaluated in combination with interferon beta. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects Pregnancy Category B. Administration of glatiramer acetate by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on offspring development. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, COPAXONE should be used during pregnancy only if clearly needed. In rats or rabbits receiving glatiramer acetate by subcutaneous injection during the period of organogenesis, no adverse effects on embryo-fetal development were observed at doses up to 37.5 mg/kg/day (18 and 36 times, respectively, the therapeutic human dose of 20 mg/day on a mg/m2 basis). In rats receiving subcutaneous glatiramer acetate at doses of up to 36 mg/kg from day 15 of pregnancy throughout lactation, no significant effects on delivery or on offspring growth and development were observed. 8.2 Labor and Delivery The effects of COPAXONE on labor and delivery in pregnant women are unknown. 8.3 Nursing Mothers It is not known if glatiramer acetate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when COPAXONE is administered to a nursing woman. 8.4 Pediatric Use The safety and effectiveness of COPAXONE have not been established in patients under 18 years of age. 8.5 Geriatric Use COPAXONE has not been studied in elderly patients. 8.6 Use in Patients with Impaired Renal Function The pharmacokinetics of glatiramer acetate in patients with impaired renal function have not been determined. 11 DESCRIPTION COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies. Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt). Its structural formula is:
COPAXONE is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 1 mL of solution contains 20 mg of glatiramer acetate and 40 mg of mannitol. The pH range of the solution is approximately 5.5 to 7.0. The biological activity of COPAXONE is determined by its ability to block the induction of experimental autoimmune encephalomyelitis (EAE) in mice. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery. Because glatiramer acetate can modify immune functions, concerns exist about its potential to alter naturally occurring immune responses. There is no evidence that glatiramer acetate does this, but this has not been systematically evaluated [see Warnings and Precautions (5.4)]. 12.3 Pharmacokinetics Results obtained in pharmacokinetic studies performed in humans (healthy volunteers) and animals support that a substantial fraction of the therapeutic dose delivered to patients subcutaneously is hydrolyzed locally. Larger fragments of glatiramer acetate can be recognized by glatiramer acetate-reactive antibodies. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study, mice were administered up to 60 mg/kg/day glatiramer acetate by subcutaneous injection (up to 15 times the human therapeutic dose of 20 mg/day on a mg/m2 basis). No increase in systemic neoplasms was observed. In males receiving the 60-mg/kg/day dose, there was an increased incidence of fibrosarcomas at the injection sites. These sarcomas were associated with skin damage precipitated by repetitive injections of an irritant over a limited skin area. In a 2-year carcinogenicity study, rats were administered up to 30 mg/kg/day glatiramer acetate by subcutaneous injection (up to 15 times the human therapeutic dose on a mg/m2 basis). No increase in neoplasms was observed. Glatiramer acetate was not mutagenic in in vitro (Ames test, mouse lymphoma tk) assays. Glatiramer acetate was clastogenic in two separate in vitro chromosomal aberration assays in cultured human lymphocytes but not clastogenic in an in vivo mouse bone marrow micronucleus assay. When glatiramer acetate was administered by subcutaneous injection prior to and during mating (males and females) and throughout gestation and lactation (females) at doses up to 36 mg/kg/day (18 times the human therapeutic dose on a mg/m2 basis) no adverse effects were observed on reproductive or developmental parameters. 14 CLINICAL STUDIES 14.1 Relapsing-Remitting Multiple Sclerosis (RRMS) Evidence supporting the effectiveness of COPAXONE in decreasing the frequency of relapses derives from 3 placebo-controlled trials, all of which used a COPAXONE dose of 20 mg/day. Study 1 was performed at a single center. Fifty patients were enrolled and randomized to receive daily doses of either COPAXONE, 20 mg subcutaneously, or placebo (COPAXONE: n=25; placebo: n=25). Patients were diagnosed with RRMS by standard criteria, and had had at least 2 exacerbations during the 2 years immediately preceding enrollment. Patients were ambulatory, as evidenced by a score of no more than 6 on the Kurtzke Disability Scale Score (DSS), a standard scale ranging from 0–Normal to 10–Death due to MS. A score of 6 is defined as one at which a patient is still ambulatory with assistance; a score of 7 means the patient must use a wheelchair. Patients were examined every 3 months for 2 years, as well as within several days of a presumed exacerbation. To confirm an exacerbation, a blinded neurologist had to document objective neurologic signs, as well as document the existence of other criteria (e.g., the persistence of the neurological signs for at least 48 hours). The protocol-specified primary outcome measure was the proportion of patients in each treatment group who remained exacerbation free for the 2 years of the trial, but two other important outcomes were also specified as endpoints: the frequency of attacks during the trial, and the change in the number of attacks compared with the number which occurred during the previous 2 years. Table 2 presents the values of the three outcomes described above, as well as several protocol specified secondary measures. These values are based on the intent-to-treat population (i.e., all patients who received at least 1 dose of treatment and who had at least 1 on-treatment assessment):
Study 2 was a multicenter trial of similar design which was performed in 11 US centers. A total of 251 patients (COPAXONE: n=125; placebo: n=126) were enrolled. The primary outcome measure was the Mean 2-Year Relapse Rate. Table 3 presents the values of this outcome for the intent-to-treat population, as well as several secondary measures:
In both studies, COPAXONE exhibited a clear beneficial effect on relapse rate, and it is based on this evidence that COPAXONE is considered effective. In Study 3, 481 patients who had recently (within 90 days) experienced an isolated demyelinating event and who had lesions typical of multiple sclerosis on brain MRI were randomized to receive either COPAXONE 20 mg/day (n=243) or placebo (n=238). The primary outcome measure was time to development of a second exacerbation. Patients were followed for up to three years or until they reached the primary endpoint. Secondary outcomes were brain MRI measures, including number of new T2 lesions and T2 lesion volume. Time to development of a second exacerbation was significantly delayed in patients treated with COPAXONE compared to placebo (Hazard Ratio = 0.55; 95% confidence interval 0.40 to 0.77; Figure 1). The Kaplan-Meier estimates of the percentage of patients developing a relapse within 36 months were 42.9% in the placebo group and 24.7% in the COPAXONE group. Figure 1: Time to Second Exacerbation Patients treated with COPAXONE demonstrated fewer new T2 lesions at the last observation (rate ratio 0.41; confidence interval 0.28 to 0.59; p < 0.0001). Additionally, baseline-adjusted T2 lesion volume at the last observation was lower for patients treated with COPAXONE (ratio of 0.89; confidence interval 0.84 to 0.94; p = 0.0001). Study 4 was a multinational study in which MRI parameters were used both as primary and secondary endpoints. A total of 239 patients with RRMS (COPAXONE: n=119; and placebo: n=120) were randomized. Inclusion criteria were similar to those in the second study with the additional criterion that patients had to have at least one Gd-enhancing lesion on the screening MRI. The patients were treated in a double-blind manner for nine months, during which they underwent monthly MRI scanning. The primary endpoint for the double-blind phase was the total cumulative number of T1 Gd-enhancing lesions over the nine months. Table 4 summarizes the results for the primary outcome measure monitored during the trial for the intent-to-treat cohort.
Figure 2 displays the results of the primary outcome on a monthly basis. Figure 2: Median Cumulative Number of Gd-Enhancing Lesions 16 HOW SUPPLIED/STORAGE AND HANDLING COPAXONE is supplied as a single-use prefilled syringe containing 1 mL of a clear, colorless to slightly yellow, sterile, nonpyrogenic solution containing 20 mg of glatiramer acetate and 40 mg of mannitol in cartons of 30 single-use prefilled syringes with 33 alcohol preps (NDC 68546-317-30). STORAGE AND HANDLING The recommended storage condition for the COPAXONE is refrigeration (2°C to 8°C / 36°F to 46°F). However, excursions from recommended storage conditions (15°C to 30°C / 59°F to 86°F) for up to one month have been shown to have no adverse impact on the product. Exposure to higher temperatures or intense light should be avoided. COPAXONE should not be frozen. If a COPAXONE syringe freezes, it should be discarded. COPAXONE contains no preservative. Do not use if the solution contains any particulate matter. 17 PATIENT COUNSELING INFORMATION [See FDA-Approved Patient Labeling (17.7)] 17.1 Pregnancy Instruct patients that if they are pregnant or plan to become pregnant while taking COPAXONE they should inform their physician. 17.2 Immediate Post-Injection Reaction Advise patients that COPAXONE may cause various symptoms after injection, include flushing, chest pain, palpitations, anxiety, dyspnea, constriction of the throat, and urticaria. These symptoms are generally transient and self-limited and do not require specific treatment. Inform patients that these symptoms may occur early or may have their onset several months after the initiation of treatment. A patient may experience one or several episodes of these symptoms. 17.3 Chest Pain Advise patients that they may experience transient chest pain either as part of the Immediate Post-Injection Reaction or in isolation. Inform patients that the pain should be transient (usually only lasting a few minutes). Some patients may experience more than one such episode, usually beginning at least one month after the initiation of treatment. Patient should be advised to seek medical attention if they experience chest pain of unusual duration or intensity. 17.4 Lipoatrophy and Skin Necrosis at Injection Site Advise patients that localized lipoatrophy, and rarely, injection site necrosis may occur at injections sites. Instruct patients to follow proper injection technique and to rotate injection areas and sites on a daily basis. 17.5 Instructions for Use Instruct patients to read the COPAXONE Patient Information leaflet carefully. Caution patients to use aseptic technique. The first injection should be performed under the supervision of a health care professional. Instruct patients to rotate injection areas and sites on a daily basis. Caution patients against the reuse of needles or syringes. Instruct patients in safe disposal procedures. 17.6 Storage Conditions Advise patients that the recommended storage condition for COPAXONE is refrigeration (36-46°F /2-8°C), although COPAXONE can be stored at room temperature (59-86°F /15-30°C) for up to one month. COPAXONE should not be exposed to higher temperatures or intense light. 17.7 FDA-Approved Patient Labeling Read this information carefully before you use COPAXONE. Read the information you get when you refill your COPAXONE prescriptions because there may be new information. This information does not take the place of your doctor's advice. Ask your doctor or pharmacist if you do not understand some of this information or if you want to know more about this medicine. What is COPAXONE? COPAXONE (co-PAX-own) is a medicine you inject to treat Relapsing-Remitting Multiple Sclerosis. Although COPAXONE is not a cure; patients treated with COPAXONE have fewer relapses. Who should not use COPAXONE?
What are the possible side effects of COPAXONE?
These are not all the possible side effects of COPAXONE. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE. Information for pregnant and nursing women
How should I use COPAXONE?
How do I inject COPAXONE? There are 3 basic steps for injecting COPAXONE prefilled syringes:
Step 1: Gather the materials
Step 2: Choose the injection site
Step 3: Give yourself the injection
What is the proper use and disposal of prefilled syringes? Each prefilled syringe should be used for only 1 injection. Throw away all used prefilled syringes in a hard-walled plastic container, such as an empty liquid laundry detergent bottle. Keep the container closed tightly and out of the reach of children. When the container is full, check with your doctor, pharmacist, or nurse about proper disposal, as laws vary from state to state. How should I store COPAXONE prefilled syringes? Keep the COPAXONE prefilled syringe carton in the refrigerator, out of the reach of children. The COPAXONE package should be refrigerated at 36-46°F (2-8°C). You can store it at room temperature, 59-86°F (15-30°C), for up to one month. Do not store COPAXONE at room temperature for longer than one month. Do not freeze COPAXONE. If a COPAXONE prefilled syringe freezes, throw it away in a proper container. COPAXONE is light sensitive. Protect it from light when not injecting. Do not use the prefilled syringe if the solution contains particles or is cloudy. General advice about prescription medicines Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use COPAXONE for a condition for which it was not prescribed. Do not give COPAXONE to other people, even if they have the same condition you have. It may harm them. This leaflet summarizes the most important information about COPAXONE. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about COPAXONE that is written for health professionals. Also, you can call Shared Solutions® for any questions about COPAXONE and its use. The phone number for Shared Solutions® is 1-800-887-8100. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
